Chronic Kidney Disease Burden in Low-Resource Settings: Regional Perspectives

Ulasi, Ifeoma; Awobusuyi, Olugbenga; Nayak, Saurabh; Ramachandran, Raja; Musso, Carlos Guido; Depine, Santos Ángel; Aroca-Martínez, Gustavo; Solarin, Adaobi U; Onuigbo, Macaulay; Luyckx, Valérie A.; Ijoma, Chinwuba K

doi:10.1016/j.semnephrol.2023.151336

Cited by 12 publications

(7 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CKD, ranked as the 10th leading cause of mortality, affects a substantial proportion of the global population, reaching up to 13% [55]. The identification of accurate biomarkers for early diagnosing of CKD is a real challenge.…”

Section: Chronic Kidney Diseasementioning

confidence: 99%

LRG1 Contributes to the Pathogenesis of Multiple Kidney Diseases: A Comprehensive Review

Chen,

Zhang,

et al. 2024

Kidney Dis

View full text Add to dashboard Cite

Background: The increasing prevalence of kidney diseases has become a significant public health issue, with a global prevalence exceeding 10%. In order to accurately identify biochemical changes and treatment outcomes associated with kidney diseases, novel methods targeting specific genes have been discovered. Among these genes, leucine-rich α-2 glycoprotein 1 (LRG1) has been identified to function as a multifunctional pathogenic signaling molecule in multiple diseases, including kidney diseases. This study aims to provide a comprehensive overview of the current evidence regarding the roles of LRG1 in different types of kidney diseases. Summary: Based on a comprehensive review, it was found that LRG1 was up-regulated in the urine, serum, or renal tissues of patients or experimental animal models with multiple kidney diseases, such as diabetic nephropathy, kidney injury, IgA nephropathy, chronic kidney diseases (CKD), clear cell renal cell carcinoma (ccRCC), end-stage renal disease, canine leishmaniosis-induced kidney disease, kidney fibrosis, and aristolochic acid nephropathy. Mechanistically, the role of LRG1 in kidney diseases is believed to be detrimental, potentially through its regulation of various genes and signaling cascades, i.e. FN1, GPR56, VEGF, VEGFR-2, DR5, GDF15, HIF-1α, SPP1, ALK1-Smad1/5/8, NLRP3-IL-1b, and TGF-β pathway. Key Messages: Further research is needed to fully comprehend the molecular mechanisms by which LRG1 contributes to the pathogenesis and pathophysiology of kidney diseases. It is anticipated that targeted treatments focusing on LRG1 will be utilized in clinical trials and implemented in clinical practice in the future.

show abstract

Section: Chronic Kidney Diseasementioning

confidence: 99%

LRG1 Contributes to the Pathogenesis of Multiple Kidney Diseases: A Comprehensive Review

Chen,

Zhang,

et al. 2024

Kidney Dis

View full text Add to dashboard Cite

show abstract

“…An estimated 13.3 million AKI episodes occur every year worldwide, 85% of which occur in the least developed or developing countries, representing a serious financial problem for the majority of people who need it, with less than 10% of patients in these settings receiving kidney replacement therapy. Many people cannot afford kidney treatment at all, resulting in the death of over 1 million people annually from untreated kidney failure [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective

González-Nicolás,

González-Guerrero,

Goicoechea

et al. 2024

IJMS

View full text Add to dashboard Cite

Contrast-Induced Acute Kidney Injury (CI-AKI) remains a frequent iatrogenic condition since radiological procedures using intra-vascular iodinated contrast media (CM) are being widely administered for diagnostic and therapeutic purposes. Despite the improvement of the medical healthcare system worldwide, CI-AKI is still associated with direct short-term and indirect long-term outcomes including increased morbidity and mortality, especially in patients with underlying pre-existing renal function impairment, cardiovascular disease, or diabetes that could rapidly progress into Chronic Kidney Disease. Although the RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease), AKIN (Acute Kidney Injury Network), and KDIGO (Kidney Disease Improving Global Outcomes) clinical criteria and recommendation guidelines are based on traditional “gold standard” biomarkers known as serum creatinine, glomerular filtration rate, and urinary output, new reliable serum and urinary biomarkers are still needed for an effective unified diagnostic strategy for AKI. Starting from previous and recent publications on the benefits and limitations of validated biomarkers responding to kidney injury, glomerular filtration, and inflammation among others, this review unravels the role of new emerging biomarkers used alone or in combination as reliable tools for early diagnosis and prognosis of CI-AKI, taking into account patients and procedures-risk factors towards a new clinical perspective.

show abstract

“…In 2022, between 4.90 and 7.08 million patients worldwide had end-stage kidney disease and need kidney replacement therapy [ 3 ]. Of note, CKD represents an especially large burden in low- and middle-income countries, which are least equipped to deal with its consequences [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Urinary podocyte markers in diabetic kidney disease

Li,

Szeto

2024

Kidney Res Clin Pract

View full text Add to dashboard Cite

Podocytes are involved in maintaining kidney function and are a major focus of research on diabetic kidney disease (DKD). Urinary biomarkers derived from podocyte fragments and molecules have been proposed for the diagnosis and monitoring of DKD. Various methods have been used to detect intact podocytes and podocyte-derived microvesicles in urine, including centrifugation, visualization, and molecular quantification. Quantification of podocyte-specific protein targets and messenger RNA levels can be performed by Western blotting or enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. At present, many of these techniques are expensive and labor-intensive, all limiting their widespread use in routine clinical tests. While the potential of urinary podocyte markers for monitoring and risk stratification of DKD has been explored, systematic studies and external validation are lacking in the current literature. Standardization and automation of laboratory methods should be a priority for future research, and the added value of these methods to routine clinical tests should be defined.

show abstract

Chronic Kidney Disease Burden in Low-Resource Settings: Regional Perspectives

Cited by 12 publications

References 69 publications

LRG1 Contributes to the Pathogenesis of Multiple Kidney Diseases: A Comprehensive Review

LRG1 Contributes to the Pathogenesis of Multiple Kidney Diseases: A Comprehensive Review

Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective

Urinary podocyte markers in diabetic kidney disease

Contact Info

Product

Resources

About